Blood and Plasma Components Market By Size, Share, Trends, Growth, Forecast 2027

Summary

Report Description

The global blood & plasma components market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing volume of surgeries, surge in the prevalence of trauma and road accidents, and increase in number of people from chronic conditions including cancer are curbing the growth of the market. Blood is life-sustaining fluid that flows throughout the body giving nourishment, electrolytes, hormones, antibodies, and vitamins to body tissues. Plasma is a part of blood which is aqueous in nature, it contains salt and proteins in which platelets, white blood cells and red blood cells are suspended. The other factors supporting the market’s growth are, rising awareness associated with the significance of blood donations, high patient pool, government initiatives, increasing investments for research and development activities, several blood donation campaigns undertaken by various blood organizations, rise in the elderly population base, rise in R&D activities, and technological advancements. Also, the strategic initiatives such as partnerships and product launches undertaken by the market players are augmenting the growth of the market.

Increasing Occurrence of Trauma and Road Accidents

The growing incidence of trauma and road accidents is a significant factor propelling the growth of the market. At times, people suffer from traumas such as hemorrhage, the amount of blood present gets reduced and cannot be replaced fast enough by the body. According to a review, in 2018, approximately 60,000 Americans die from hemorrhaging or blood loss, every year. Also, owing to rise in numbers of road accidents, excessive blood loss from the body is rising the demand for blood or plasma transfusion to prevent bleeding. Thus, in turn, these situations are augmenting the growth of the blood and plasma component market, globally. According to WHO research in 2020, nearly 1.5 million people die every year due to road traffic injuries around the globe.

Rising Frequency of Blood Diseases and Surgeries

The growing incidences of bleeding disorders and rising number of surgeries across the globe is bolstering the growth of the market. Hemophilia A and B, and von Willebrand disease are the most common bleeding disorders. For instance, in 2019, 195,263 people globally were diagnosed with hemophilia and 80,302 who were diagnosed with von Willebrand disease. In addition to these, increasing cases of surgeries are impelling the growth of the market as lot of blood is loss during the operations which increases the chances of needing transfusions. Also, demand for blood transfusion rises in patients who are anemic. For instance, approximately 310 million major surgeries are performed every year, globally, in which 50 million in USA and 20 million in Europe.

Increasing Adoption of Inorganic Growth Strategies

Various inorganic growth strategies such as mergers, collaborations, acquisitions, and partnerships are supporting the growth of the market. For instance, the Blood Center of Wisconsin collaborated with SysLogic Inc., to research how the RFID technology can be utilized to heighten safety of the patient while collecting and transfusing blood products. Similarly, in 2018, Invitrx Inc. launched a cord blood plasma product that contains plasticity-promoting proteins that may have anti-aging effects that increase neurogenesis and cognitive function.

Download Free Sample Report

Market Segmentation

The global blood & plasma components market is segmented into products, application, end user and company. Based on products, the market is divided into packed red blood cells, platelets products, frozen plasma, and plasma derived products. Based on plasma derived products, the market is further divided into immunoglobulins, albumins, coagulation factor concentrates, and others. Based on application, the market is divided into hematology, solid tumor management, and others. Based on hematology, the market is further divided into hemoglobinopathy, hematologic malignancies treatment, coagulopathy, and others. Based on end user, the market is divided into hospitals & clinics, diagnostic laboratories, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising number of chronic diseases and surgeries in the country.

Market Players

CSL Limited, Grifols S.A., ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., LFB S.A., and Versiti, Inc. are some of the leading companies operating in the market.

Attribute	Details
Base Year	2021
Historic Data	2017 – 2020
Estimated Year	2022
Forecast Period	2023 – 2027
Quantitative Units	Revenue in USD Million, Volume Units and CAGR for 2017-2021 and 2022-2027
Report coverage	Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends
Segments covered	· Products · Application · End User · Company
Regional scope	North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa
Country scope	United States; Canada; Mexico; China; India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa
Key companies profiled	CSL Limited, Grifols S.A., ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., LFB S.A., and Versiti, Inc.
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global blood & plasma components market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

· Blood & Plasma Components Market, By Products:

Packed Red Blood Cells
Platelets Products
Frozen Plasma
Plasma Derived Products

§ Immunoglobulins

§ Albumins

§ Coagulation Factor Concentrates

§ Others

· Blood & Plasma Components Market, By Application:

Hematology

§ Hemoglobinopathy

§ Hematologic Malignancies Treatment

§ Coagulopathy

§ Others

Solid Tumor Management
Others

· Blood & Plasma Components Market, By End User:

Hospitals & Clinics
Diagnostic Laboratories
Others

· Blood & Plasma Components Market, By Region:

North America

United States
Canada
Mexico

Asia-Pacific

China
India
Japan
Australia
South Korea

Europe & CIS

Germany
France
United Kingdom
Spain
Italy

South America

Brazil
Argentina
Colombia

Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Blood & Plasma Components Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Blood & Plasma Components Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Blood & Plasma Components Market

5. Voice of Customer

6. Global Blood & Plasma Components Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)

6.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)

6.2.2. By Application (Hematology, Solid Tumor Management, Others)

6.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)

6.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)

6.2.4. By Company (2021)

6.2.5. By Region

6.3. Market Map

7. North America Blood & Plasma Components Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)

7.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)

7.2.2. By Application (Hematology, Solid Tumor Management, Others)

7.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)

7.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)

7.2.4. By Country

7.3. North America: Country Analysis

7.3.1. United States Blood & Plasma Components Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Products

7.3.1.2.2. By Application

7.3.1.2.3. By End User

7.3.2. Canada Blood & Plasma Components Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Products

7.3.2.2.2. By Application

7.3.2.2.3. By End User

7.3.3. Mexico Blood & Plasma Components Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Products

7.3.3.2.2. By Application

7.3.3.2.3. By End User

8. Europe Blood & Plasma Components Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)

8.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)

8.2.2. By Application (Hematology, Solid Tumor Management, Others)

8.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)

8.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)

8.2.4. By Country

8.3. Europe: Country Analysis

8.3.1. France Blood & Plasma Components Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Products

8.3.1.2.2. By Application

8.3.1.2.3. By End User

8.3.2. Germany Blood & Plasma Components Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Products

8.3.2.2.2. By Application

8.3.2.2.3. By End User

8.3.3. United Kingdom Blood & Plasma Components Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Products

8.3.3.2.2. By Application

8.3.3.2.3. By End User

8.3.4. Italy Blood & Plasma Components Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Products

8.3.4.2.2. By Application

8.3.4.2.3. By End User

8.3.5. Spain Blood & Plasma Components Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Products

8.3.5.2.2. By Application

8.3.5.2.3. By End User

9. Asia-Pacific Blood & Plasma Components Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)

9.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)

9.2.2. By Application (Hematology, Solid Tumor Management, Others)

9.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)

9.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)

9.2.4. By Country

9.3. Asia-Pacific: Country Analysis

9.3.1. China Blood & Plasma Components Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Products

9.3.1.2.2. By Application

9.3.1.2.3. By End User

9.3.2. India Blood & Plasma Components Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Products

9.3.2.2.2. By Application

9.3.2.2.3. By End User

9.3.3. Japan Blood & Plasma Components Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Products

9.3.3.2.2. By Application

9.3.3.2.3. By End User

9.3.4. South Korea Blood & Plasma Components Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Products

9.3.4.2.2. By Application

9.3.4.2.3. By End User

9.3.5. Australia Blood & Plasma Components Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Products

9.3.5.2.2. By Application

9.3.5.2.3. By End User

10. South America Blood & Plasma Components Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)

10.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)

10.2.2. By Application (Hematology, Solid Tumor Management, Others)

10.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)

10.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)

10.2.4. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Blood & Plasma Components Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Products

10.3.1.2.2. By Application

10.3.1.2.3. By End User

10.3.2. Argentina Blood & Plasma Components Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Products

10.3.2.2.2. By Application

10.3.2.2.3. By End User

10.3.3. Colombia Blood & Plasma Components Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Products

10.3.3.2.2. By Application

10.3.3.2.3. By End User

11. Middle East and Africa Blood & Plasma Components Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)

11.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)

11.2.2. By Application (Hematology, Solid Tumor Management, Others)

11.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)

11.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)

11.2.4. By Country

11.3. MEA: Country Analysis

11.3.1. South Africa Blood & Plasma Components Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Products

11.3.1.2.2. By Application

11.3.1.2.3. By End User

11.3.2. Saudi Arabia Blood & Plasma Components Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Products

11.3.2.2.2. By Application

11.3.2.2.3. By End User

11.3.3. UAE Blood & Plasma Components Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Products

11.3.3.2.2. By Application

11.3.3.2.3. By End User

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

14.1. CSL Limited

14.2. Grifols S.A.

14.3. ADMA Biologics, Inc.

14.4. Takeda Pharmaceutical Company Limited

14.5. Octapharma AG

14.6. Kedrion S.p.A

14.7. Emergent BioSolutions Inc.

14.8. Bio Products Laboratory Ltd.

14.9. LFB S.A.

14.10. Versiti, Inc.

15. Strategic Recommendations

Figures and Tables

Frequently asked questions

What are the major drivers for the Global Blood & Plasma Components Market?

Growing volume of surgeries, surge in the prevalence of trauma and road accidents, and increase in number of people from chronic conditions including cancer are driving the demand for the global blood & plasma components market.

Who are the top players operating in the Global Blood & Plasma Components Market?

CSL Limited, Grifols S.A., ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., LFB S.A., and Versiti, Inc. are the key players operating in the global blood & plasma components market.

What are the key factors hampering growth for the Global Blood & Plasma Components Market?

The rising risk of developing or transferring an infection, lesser number of blood banks, and high costs of blood plasma treatments may hamper the growth of the global blood & plasma components market.

What is the study period of this market?

The global blood & plasma components market is studied from 2017 to 2027.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Blood & Plasma Components Market to be dominated by Growing Occurrences of Chronic Diseases and Surgeries through 2027

Sep, 2022

Growing prevalence of blood disorders and rise in number of road accidents to drive the blood & plasma components market in the forecast period, 2023-2027.

Buy Now